Abstract
Plasma exchange, or plasmapheresis, was first introduced for the treatment of homozygous familial hypercholesterolaemia more than 10 years ago (1), Since then it has become increasingly clear that twice monthly exchanges with plasma protein fraction (PPF) provide a safe and effective means of treating this potentially fatal condition. Several patients have undergone this regimen for over 9 years without any significant acute complications or long-term side-effects. Mean plasma cholesterol levels have been reduced to 50% of untreated values (2) and this has been accompanied by gradual disappearance of cutaneous and tendon xanthomata. However, there has been little evidence of regression of atheromatous lesions in the root of the aorta or coronary arteries, although the impression is that progression of such lesions has been arrested or slowed (3). Analysis of the life-span of 5 homozygous sibling pairs, one member of each being treated by plasma exchange and the other not, shows that this form of treatment improves the chances of survival (unpublished data).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.R. Thompson, R. Lowenthal and N.B. Myant, Plasma exchange in the management of homozygous familial hypercholesterolaemia, Lancet 1:1208 (1975).
G.R. Thompson, Plasma exchange for hypercholesterolaemia, Lancet 1:1246 (1981).
G.R. Thompson, N.B. Myant, D. Kilpatrick, CM. Oakely, M.J. Raphael and R.E. Steiner, Assessment of long-term plasma exchange for familial hypercholesterolaemia, Brit. Heart J. 43:680 (1980).
D.P. Barr, Some chemical factors in the pathogenesis of atherosclerosis, Circulation 8:641 (1953).
G.S. Miller and N.E. Miller, Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease, Lancet 1:16 (1975).
K. Berg, A.L. Borresen and G. Dahlen, Serum-high-density-lipoprotein and atherosclerotic heart disease, Lancet 1:499 (1976).
T. Ishikawa, N. Fidge, D.S. Thelle, O.H. Forde and N.E. Miller, The Tromso Heart Study: serum apolipoprotein AI concentration in relation to future coronary heart disease, Eur. J. Clin. Invest. 8:179 (1978).
G.G. Rhoads, C.L. Gulbrandsen and A. Kagan, Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men, New Eng. J. Med. 294:293 (1976).
W.P. Castelli, J.T. Doyle, T. Gordon, C. G. Harnes, M.C. Hjortland, S.B. Hulley, A. Kagan and W.J. Zukel, HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein pheno-typing study, Circulation 55:767 (1977).
S. Yaari, U. Goldbourt, Z. Even-Zohar and H.N. Neufeld, Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular and cancer mortality in a 7-year prospective study of 10,000 men, Lancet 1:1011 (1981).
P.J. Jenkins, R.W. Harper and P.J. Nestel, Severity of coronary atherosclerosis related to lipoprotein concentration, Brit. Med. J. 2:388 (1978).
T.A. Pearson, B.H. Bulkley, S.C. Achuff, P.O. Kwiterovich and L. Gordis, The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease, Amer. J. Epidem. 109:285 (1979).
J.J. Maciejko, D.R. Holmes, B.A. Kottke, A.R. Zinsmeister, D.M. Dinh and S.J.T. Mao, Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease, New Eng. J. Med. 309:385 (1983).
A. Angel, S. Thanabalasingham, D. Reichl, J.J. Pflug, G.R. Thompson and N.B. Myant, Effects of starvation and plasma exchange on lecithin: cholesterol acyltransferase activity and cholesterol efflux in cholesterol-fed pigs, Res. Exp. Med. 184:231 (1984).
S. Thanabalasingham, G.R. Thompson, I. Trayner, N.B. Myant and A.K. Soutar, Effect of lipoprotein concentration and lecithin: cholesterol acyltransferase activity on cholesterol esterification in human plasma after plasma exchange, Eur. J. Clin. Invest. 10:45 (1980).
O. Zierenberg, G. Assmann, G. Schmitz and M. Rosseneu, Effect of polyenephosphatidylcholine on cholesterol uptake by human high density lipoprotein, Atherosclerosis 39:527 (1981).
A. Postiglione, B.L. Knight, A.K. Soutar and G.R. Thompson, Comparison of cholesterol efflux induced by exogenous phospholipid in vitro and during plasma exchange, in press.
C.W.M. Adams and Y.J. Abdulla, The action of human high density lipoprotein on cholesterol crystals. Part 1. Light-microscopic observations, Atherosclerosis 31:465 (1978).
C.W.M. Adams, Y.H. Abdulla, O.B. Bayliss and R.S. Morgan, Modification of aortic atheroma and fatty liver in cholesterol-fed rabbits by intravenous injection of saturated and polyunsaturated lecithins, J. Path. Bact. 94:77 (1967).
P. Dewailly, E. Decoopman, C. Desreumaux and J.C. Fruchart, Plasma removal of intravenous essential phospholipids in man, in “Phosphatidylcholine,” H. Peeters, ed., Springer Verlag, Berlin, pp 80–86 (1976).
O. Stein and Y. Stein, The removal of cholesterol from Landschlitz ascites cells by high-density apolipoprotein, Biochem. Biophys. Acta 326:232 (1973).
Y. Stein, M.C. Glangeaud, M. Fainaru and O. Stein, The removal of cholesterol from aortic smooth muscle cells in culture and Landschlitz ascites cells by fractions of human high-density apolipoprotein, Biochem. Biophys. Acta 380:106 (1975).
M. Friedman, S.O. Byers and R.H. Rosenman, Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion, Proc. Sco. Exp. Biol. Med. 95:586 (1957).
CL. Malmendier, C. Delcroix and J.P. Ameryckx, In vivo metabolism of human apoprotein A-I-phospholipid complexes. Comparison with human high density lipoprotein — apoprotein A-I metabolism, Clin. Chem. Acta 131:201 (1983).
P-J. Lupien, S. Moorjani and J. Awad, A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography, Lancet 1:1261 (1976).
W. Stoffel, H. Borberg and V. Greve, Application of specific extra-corporeal removal of low density lipoprotein in familial hypercholesterolaemia, Lancet 2:1005 (1981).
S. Yokoyama, R. Hayashi, T. Kikkawa, N. Tani, S. Takada, K. Hatanaka and A. Yamamoto, Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits, Arteriosclerosis 4:276 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer Science+Business Media New York
About this chapter
Cite this chapter
Thompson, G.R., Jadhav, A. (1986). Control of Plasma HDL Levels After Plasmapheresis. In: Angel, A., Frohlich, J. (eds) Lipoprotein Deficiency Syndromes. Advances in Experimetal Medicine and Biology, vol 201. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1262-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1262-8_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1264-2
Online ISBN: 978-1-4684-1262-8
eBook Packages: Springer Book Archive